Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-2: Esketamine in TRD
NCT02418585Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of esketamine in treatment-resistant depression (TRD), sponsored by Janssen Pharmaceutical. Started Aug 2015; status: completed.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT02418585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418585.